A minor suggestion to extend your timeframe to Sept 4th, 2019 or shortly thereafter. Although several major conferences (Vascular Discovery, EAS, ADA, ERA-EDTA, AAIC) occur prior to August 1st, at which full results may be presented, it is also possible that full results are withheld for presentation at European Society for Cardiology (ESC) August 31 to Sept 4, 2019 in Paris. This ESC conference seems to be a Resverlogix family favorite (and right around Don's birthday if I remember correctly). It is uncommon for a %RRR to be revealed in top-line data announcements. Yes, Amarin did but that was a rare exception to the trend. Usually, top-line news releases announce whether the trial successfully met the primary endpoint or failed to meet the primary endpoint. %RRR comes later with full data presentation. As for a share price......that might depend on how much dilution occurs between now and then. But based on how the market responded to Amarin's REDUCE-IT trial for Vascepa, a market cap of $5 billion with a 30% RRR would not be far fetched. Based on today's share count, this would be ~$25 USD per share.

BearDownAZ